Amycretin
About
About Amycretin
Amycretin is a unimolecular fusion peptide combining GLP-1 receptor agonism with amylin receptor agonism in a single molecule, developed by Novo Nordisk as the next evolution beyond semaglutide. Phase I data showed extraordinary weight loss of approximately 13% over just 12 weeks — suggesting potential for 25%+ reductions at full treatment duration. It represents the first clinically advanced GLP-1/amylin combination in a single molecular entity.
Science
Mechanism of Action
Simultaneously activates GLP-1 receptors to suppress appetite and slow gastric emptying, and amylin receptors in the area postrema and hypothalamus to independently reduce food intake and body weight through complementary and additive satiety pathways.
Dosing
Typical Protocol
Weekly subcutaneous injection; Phase I doses not publicly disclosed; Phase II ongoing as of 2025.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
No verified providers offering Amycretin yet
We audit new providers every week. Leave your email and we’ll let you know as soon as a Vial-verified provider starts offering Amycretin.
Free. We’ll only email when there’s a real match.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.